http://orcid.org/0000-0002-9482-7660
References
- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–962.
- Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ. 2014;349:g4670.
- HEMOCLOT Thrombin Inhibitors Package Insert, reference CK002K. Available at: http://www.aniara.com/pdf/INS-ACK002K.pdf. Accessed July 2015.
- Hyphen Biomed. Application Sheet for Dabigatran with Hemoclot Thrombin Inhibitors v3. Available at: http://www.aniara.com/pdf/ADA-ACK002KLCS2000i-2100i.pdf. [last accessed July 2015].
- Bonini P, Plebani M, Ceriotti F, Rubboli F. Errors in laboratory medicine. Clin Chem 2002;48:691–8.
- Dabigatran Plasma Calibrator Ref 222801. Available at: http://www.aniara.com/pdf/INS-A222801.pdf. [last accessed 1 Nov 2017].
- BIOPHEN® Dabigatran Calibrator Low Ref 222901. Available at: http://www.aniara.com/pdf/INS-A222901.pdf. [last accessed 1 Nov 2017].
- BIOPHEN® Dabigatran Calibrator Low Ref 225001. Available at: http://www.aniara.com/pdf/INS-A225001.pdf. [last accessed 1 Nov 2017].
- Dabigatran Control Plasma Ref 224701. Available at: http://www.aniara.com/pdf/INS-A224701.pdf. [last accessed 1 Nov 2017].
- Lassen JF, Brandslund I, Antonsen S. International normalized ratio for prothrombin times in patients taking oral anticoagulants: critical difference and probability of significant change in consecutive measurements. Clin Chem 1995;41:444–7.
- Boonen K, Schmitz E, Rozestraten F, van den Heuvel D, Brunsveld L, van der Voort P, van de Kerkhof D. Real life dabigatran and metabolite concentrations, focused on inter-patient variability and assay differences in patients with atrial fibrillation. Clin Chem Lab Med 2017;55:2002–9.
- Rasmuson A, Berndtsson M, Soderblom L, Skeppholm M, Malmstrom R, Antovic J, Evaluation of different coagulation laboratory methods to monitor apixaban, rivaroxaban and dabigatran treatment. The XXVI Congress of the International Society on Thrombosis and Haemostasis, poster presentation; 2017 Jul 8–13; City Cube, Berlin, Germany.
- Steiner T, Bohm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, Laufs U, Nickenig G, Riess H, Röther J, Schellinger PD, Spannagl M, Veltkamp R. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 2013;102:399–412.
- Schmitz EM, Boonen K, van den Heuvel DJ, van Dongen JL, Schellings MW, Emmen JM, van der Graaf F, Brunsveld L, van de Kerkhof D. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 2014;12:1636–46.